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Cancer susceptibility loci identified in reported genome-wide association studies (GWAS) are often tumor-specific; however, evidence
of pleiotropy of some genes/loci has also been observed and biologically plausible. We hypothesized that there are important regions
in the genome harboring genetic variants associated with risk of multiple types of cancer. In the current study, we attempted to map
genetic variants that have consistent effects on risk of multiple cancers using our existing genome-wide scan data of lung cancer, non-
cardia gastric cancer, and esophageal squamous-cell carcinoma with overall 5,368 cases and 4,006 controls (GWAS stage), followed by
a further evaluation in additional 9,001 cases with one of these cancer types and 11,436 controls (replication stage). Five variants
satisfying the criteria of pleiotropy with p values from 1.10 3 108 to 8.96 3 106 for genome-wide scans of three cancer types were
further evaluated in the replication stage. We found consistent associations of rs2494938 at 6p21.1 and rs2285947 at 7p15.3 with these
three cancers in both GWAS and replication stages. In combined samples of GWAS and replication stages, the minor alleles of rs2494938
and rs2285947 were significantly associated with an increased risk of the cancers (odds ratio [OR] ¼ 1.15, 95% confidence interval [CI],
1.10–1.19 and OR ¼ 1.17, 95% CI, 1.12–1.21), with the p values being 1.20 3 1012 and 1.26 3 1016, respectively, which are at
a genome-wide significance level. Our findings highlight the potential importance of variants at 6p21.1 and 7p15.3 in the susceptibility
to multiple cancers.Genome-wide association studies (GWAS) have broadened
our understanding of genetic variations that confer risk
for different types of cancers.1 Notably, most of risk-related
loci are tumor-specific. However, pleiotropy has been
observed for several loci, such as the regions of 8q24,
5p15.33 (TERT [MIM 187270]-CLPTM1L [MIM 612585]),
and 9p21.3 (ANRIL [MIM 613149]). Among several loci
at 8q24 associated with prostate cancer risk,2–8 at least
two have also been associated with risk of colorectal
cancer,9–11 ovarian cancer,12 or breast cancer.13 Prelimi-
nary results from functional studies have linked a cancer-
related variant (rs6983267) at 8q24 to an enhancer that
may interact with the known oncogene MYC [MIM
190080].14,15 The TERT-CLPTM1L locus has initially been
implicated in lung cancer risk.16,17 In a subsequent study
on 17 cancer types, the variant rs401681 allele at the
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cervical cancers, whereas it conferred protection against
cutaneous melanoma.18 Furthermore, this locus is also
associated with risk of cancers of glioma,19 pancreas,20
and breast.21 The ANRIL locus at 9p21.3 is associated with
risk of coronary artery disease,22 myocardial infarction,23
type 2 diabetes,24 and multiple cancers (glioma,19,25 basal
cell carcinoma,26 melanoma,27 breast,28 and nasopharyn-
geal carcinoma29). Importantly, mouse models have re-
vealed a pivotal role of Anril in regulation of CDKN2A/B
through and in proliferation and senescence.30 Thus,
evidence of pleiotropy might highlight some common
etiological pathways in the development of multiple
human cancers.
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cancer. To test this hypothesis, we utilized the existing
GWAS data on lung cancer,31 noncardia gastric cancer
(NCGC),32 and esophageal squamous-cell carcinoma
(ESCC)33 that have been associated with a common risk
factor of cigarette smoking34–36 and may have shared
susceptibility loci, to map pleiotropic loci contributing to
these three types of cancer in Han Chinese populations,
followed by further replication in an additionally large
case-control set.
Subjects included in the current study and the criteria for
their recruitment have been described previously.31–33
Briefly, for the GWAS stage, 1,473 cases with lung cancer,
550 cases with NCGC, and their shared 1,962 controls
were recruited from central region of China (Jiangsu Prov-
ince and surrounding areas); 858 cases with lung cancer,
456 cases with NCGC, 2,031 cases with ESCC, and their
shared 2,044 controls were recruited from northern region
of China (Beijing and surrounding areas). In the replication
stage, 1,894 cases with NCGC, 3,006 cases with ESCC, and
6,525 controls were recruited from Jiangsu Province and
surrounding areas; 1,534 cases with lung cancer, 1,436
cases with NCGC, and 2,922 controls were recruited from
Beijing and surrounding areas. An additional set of 1,131
cases with lung cancer and 1,989 controls was recruited
from southern region of China (Guangdong Province).
Overall, 5,368 cancer cases and 4,006 controls were
included in the GWAS stage, and 9,001 cancer cases
(2,665 lung cancer, 3,330 NCGC, and 3,006 ESCC) and
11,436 controls were included in the replication stage. All
of these subjects provided informed consent. This study
was approved by the Institutional Review Boards of all
participating institutions.
All samples in the GWAS stage were scanned using
Affymetrix Genome-Wide Human SNP Array 6.0 chips
(Affymetrix), as described previously.31–33 Standard quality
control procedures on the raw genotyping data were used
to filter unqualified samples and SNPs. Individuals were
removed from subsequent analyses if they satisfy any of
the following items: (1) low call rate (overall rat < 95%),
(2) ambiguous gender, (3) duplicates or familial relation-
ship (PI_HAT > 0.025), (4) extreme heterozygosity rate
(> mean þ 6 SD). SNPs were excluded if they (1) were
not mapped to autosome chromosomes, (2) had a call
rate < 95%, (3) had minor allele frequency (MAF) < 0.05
in controls, (4) had genotype distributions that deviated
from those expected as Hardy-Weinberg equilibrium in
controls (p < 1 3 105), or (5) failed in any of quality
control for GWAS of lung cancer, noncardia gastric cancer,
and esophageal squamous-cell carcinoma. As a result,
2,331 cases with lung cancer, 1,006 cases with NCGC,
2,031 cases with ESCC and 4,006 controls retained for
the association analyses in the GWAS stage.
Association analyses in the GWAS stage were first per-
formed independently in lung cancer, NCGC and ESCC,
and in the cohorts from different areas (Central and
Northern). The results from different cohorts for NCGC
or ESCC were combined by meta-analysis. Pleiotropic lociThe Americanwere then defined and selected for further confirmation
in replication stage according to the following criteria:
(1) SNPs had consistent associations (p < 0.05) between
Central and Northern cohorts for each cancer, (2) con-
sistent associations were shown for all three types of
cancer, and (3) p % 1.0 3 105 for the combined results
of three types of cancer in the GWAS stage. As a result,
five SNPs were selected for genotyping (see Table S1 avail-
able online) in the replication stage using TaqMan assays
(Applied Biosystems, Foster City, CA). Sample status (case
or control) was blinded to laboratory technicians who
performed genotyping. Ten percent of random samples
were repeated for rs2494938 and rs2285947, and the over-
all accordance rates were 99.8% and 99.7%, respectively.
We performed logistic regression analyses indepen-
dently based on additive model with adjustment for first
principal component, age, sex, and smoking status on
each GWAS. For NCGC and lung cancer studies in the
GWAS stage, we first treated the samples from two cohorts
as independent studies (Central and Northern), and then
combined the results for each cancer by meta-analysis.
Because the shared controls were used for Central or
Northern studies in GWAS stage, the combined association
results of the three cancers for filtered SNPs with consistent
association results were analyzed by pooling all cancer
cases together as compared with the shared controls. The
same analysis approach was used in the replication stage.
The results from GWAS and replication stages or from
different regions (Central, Northern, and Southern) were
combined by either pooling samples together or using
meta-analysis. Similar results were observed for these two
approaches and the former one was reported as default in
this study unless specified. Meta-analysis was performed
in a default fixed-effect model with inverse variance
weighted and a calculation of Cochran’s Q statistics for
homogeneity test. A random-effects model (DerSimo-
nian-Laird) was adopted and the corresponding results
were reported if there was indication of heterogeneity
between groups (PQ % 0.05). Otherwise, the fixed effect
model was maintained (PQ > 0.05). PLINK 1.07 was used
for genetic association analysis.37 Analyses were also per-
formed using SAS version 9.1.3 (SAS Institute, Cary, NC)
or Stata version 9.2 (StataCorp LP, TX).
The characteristics of 5,368 cases and 4,006 controls
included in the GWAS of three types of cancer are shown
in Table 1. We first performed logistic regression analyses
based on additive model with adjustment for the first
principal component, age, sex, and smoking status on
each GWAS independently. For lung cancer and NCGC
studies, we treated the samples from two cohorts as
independent studies (Central study and Northern study),
and then estimated combined effect of each locus
by meta-analysis.31,33 Pleiotropic loci were defined as
having consistent effects among three types of cancer
and between Central and Northern studies in GWAS.
As a result, 5 SNPs (rs2399395 at 3q13.2, rs2494938 at
6p21.1, rs2285947 at 7p15.3, rs13232645 at 7q22.1, andJournal of Human Genetics 91, 928–934, November 2, 2012 929
Table 1. Characteristics of Cases with Lung Cancer, Noncardia Gastric Cancer, or Esophageal Squamous-Cell Carcinoma and Controls
Included in GWAS and Replication Stages
Studies Data Set Region No. Age (Mean 5 SD) Sex (males, %)
Smoking Status
(smokers, %)
Total cases 14,369 59.53 5 10.68 72.19 50.09
Lung cancer GWAS Central 1,473 60.08 5 10.30 71.76 44.81
GWAS Northern 858 60.00 5 10.23 76.22 59.91
Replication Northern 1,534 58.14 5 9.71 67.08 59.97
Replication Southern 1,131 60.27 5 12.32 70.73 55.88
NCGC GWAS Central 550 58.24 5 11.91 71.27 44.91
GWAS Northern 456 56.79 5 12.42 70.61 28.29
Replication Central 1,894 58.71 5 11.97 70.49 46.73
Replication Northern 1,436 57.06 5 12.11 69.29 25.49
ESCC GWAS Northern 2,031 59.84 5 9.78 80.11 65.24
Replication Central 3,006 61.70 5 8.54 71.92 50.57
Total controls 15,442 59.00 5 11.73 70.24 43.70
GWAS Central 1,962 59.35 5 9.74 61.88 53.82
GWAS Northern 2,044 61.34 5 8.55 83.46 38.38
Replication Central 6,525 58.32 5 11.92 68.29 28.64
Replication Northern 2,922 58.24 5 12.86 70.12 68.62
Replication Southern 1,989 59.59 5 13.49 71.49 51.33rs9982863 at 21q22.3) were identified (Table S1). Because
similar frequency and effect on the three types of cancer
were observed across studies each of these 5 SNPs, the
subjects from different studies were combined directly
to test the associations. We observed that the combined
p values were 1.10 3 108 to 8.96 3 106 for these five
SNPs (Table S1).
We next performed replications of above five promising
SNPs in overall 9,001 cases with three types of cancer
(2,665 lung cancer, 3,330 NCGC, and 3,006 ESCC) and
11,436 controls. We found that rs2399395 at 3q13.2
and rs13232645 at 7q22.1 were replicated only in ESCC
and lung cancer (nominal p < 0.05), respectively, whereas
rs9982863 at 21q22.3 was not significantly associated
with any type of cancer (Table S2). Thus, these three
SNPs were not further investigated. The remaining two
SNPs, rs2494938 at 6p21.1 and rs2285947 at 7p15.3,
were both associated with all three types of cancer. In com-
bined sample, the odds ratios (ORs) for rs2494938 and
rs2285947 were 1.15 (95% confidence interval [CI], 1.10–
1.19; p ¼ 1.20 3 1012) and 1.17 (95% CI, 1.12–1.21;
p ¼ 1.26 3 1016), respectively (Table 2). For both
rs2494938 and rs2285947, no significant heterogeneity
of associations was observed between the GWAS and repli-
cation studies or among the Northern, Central, and
Southern cohorts (all pQ > 0.05) (Figure S1).
To further characterize the loci at 6p21.1 and 7p15.3
associated with risk of multiple cancers, we imputed
untyped SNPs in the flanking regions of rs2494938 and930 The American Journal of Human Genetics 91, 928–934, Novembrs2285947 within a 250 kb window for subjects in the
GWAS stage using the CHBþJPT data from the 1000
Genomes database (released at June 2010) as reference
haplotype using Minimac software. Regional plots were
generated by three cancer types according to p value of
association for each SNP using LocusZoom.38 As shown
in Figure S2, SNPs with lower p values at both regions
were observed for each cancer. After conditioning on
lead SNP (rs2494938 or rs2285947) for respective region,
none of the associations were found with a p < 0.001 for
the remaining SNPs at 6p21.1 and 7p15.3 except for
association of variants at 7p15.3 with ESCC risk, suggest-
ing that no additional independent loci exist at these
two regions for lung cancer and NCGC. However, further
studies are warranted to assess the independence of associ-
ations of variants at 7p15.3 with ESCC risk.
With an effort to show potential biofeatures of associa-
tion, the locus at 6p21.1 was annotated based on UCSC
genome browser (Figure S3). SNPs in strong LD with
rs2494938 at 6p21.1 are located in the initial region
(including promoter, exon 1, and intron 1) of LRFN2
[MIM 612808] (encoding leucine-rich repeat and fibro-
nectin type III domain-containing protein 2), a member
of synaptic adhesion-like molecules (SALMs) family
that interacts with the N-methyl D-aspartate (NMDA)
receptor.39 It has been reported that the LRFN2 can subvert
hematopoietic differentiation to increase erythropoiesis
and lead to erythroblastosis in cooperation with MYC.40
NMDA receptors are glutamate receptors, consisting ofer 2, 2012
Table 2. Associations of rs2494938 at 6p21.1 and rs2285947 at 7p15.3 with the Risks of Lung Cancer, Noncardia Gastric Cancer, and
Esophageal Squamous-Cell Carcinoma
Studies
6p21.1: rs2494938 (G/A)a 7p15.3: rs2285947 (G/A)a
N (cases/
controls)
MAFb
(cases/
controls) OR (95%CI)c pc
N (cases/
controls)
MAFb
(cases/
controls) OR (95%CI)c pc
Lung Cancer
GWAS-Central 1,473/1,962 0.24/0.22 1.13(1.01–1.26) 3.70 3 102 1,457/1,947 0.29/0.27 1.12(1.00–1.24) 4.69 3 102
GWAS-Northern 858/2,044 0.25/0.22 1.18(1.03–1.35) 1.42 3 102 856/2,044 0.31/0.26 1.24(1.09–1.41) 7.48 3 104
Replication-
Northern
1,534/2,905 0.25/0.23 1.13(1.02–1.25) 2.21 3 102 1,526/2,986 0.32/0.28 1.19(1.08–1.31) 4.45 3 104
Replication-
Southern
1,114/1,971 0.27/0.23 1.18(1.05–1.33) 4.86 3 103 1,118/1,976 0.25/0.22 1.14(1.01–1.29) 2.90 3 102
Combined 4,979/8,882 0.25/0.23 1.15(1.08–1.22) 1.95 3 106 4,957/8,863 0.29/0.26 1.17(1.11–1.24) 1.57 3 108
NCGC
GWAS-Central 550/1,962 0.26/0.22 1.25(1.07–1.46) 3.94 3 103 546/1,947 0.30/0.27 1.19(1.03–1.38) 1.92 3 102
GWAS-Northern 456/2,044 0.26/0.22 1.31(1.10–1.55) 2.34 3 103 434/2,044 0.33/0.26 1.41(1.19–1.66) 5.64 3 105
Replication-
Central
1,882/6,488 0.26/0.23 1.17(1.07–1.27) 3.01 3 104 1,876/6,452 0.29/0.27 1.11(1.02–1.20) 1.55 3 102
Replication-
Northern
1,434/2,905 0.26/0.23 1.16(1.03–1.30) 1.22 3 102 1,431/2,896 0.30/0.28 1.10(0.99–1.23) 8.62 3 102
Combined 4,322/13,399 0.26/0.23 1.18(1.12-1.25) 4.91 3 109 4,287/13,339 0.30/0.27 1.14(1.08–1.21) 1.36 3 106
ESCC
GWAS-Northern 2,031/2,044 0.26/0.22 1.23(1.11–1.37) 8.82 3 105 2,029/2,044 0.31/0.26 1.23(1.12–1.36) 2.67 3 105
Replication-
Central
2,990/6,488 0.25/0.24 1.09(1.01–1.18) 2.48 3 102 2,985/6,452 0.29/0.27 1.10(1.02–1.18) 9.40 3 103
Combined 5,021/8,532 0.25/0.23 1.13(1.06–1.20) 5.58 3 105 5,014/8,496 0.30/0.27 1.14(1.08–1.21) 3.24 3 106
All combined 14,322/15,370 0.25/0.23 1.15(1.10–1.19) 1.20 3 1012 14,258/15,315 0.30/0.27 1.17(1.12–1.21) 1.26 3 1016
aMajor/minor alleles.
bMAF: minor allele frequency.
cOdds ratios (ORs), 95% confidence intervals (CIs), and p values were calculated in additive models with adjustment for age, sex, and smoking status.NR1 and NR2 (2A to 2D) subunits.41,42 NMDA receptor 2B
(NR2B) is methylated in ESCC and non-small cell lung
cancer and exhibit a tumor-suppressive activity.43,44 Inter-
estingly, it is recently revealed that NMDA channels
may play an important proapoptotic function in gastric
surface epithelial cells and regulate cell survival and death
pathways during development of gastric cancers associated
with H. pylori infection.45 However, the exact mechanism
of the locus at 6p21.1 is largely unknown though LRFN2
might function as a susceptibility gene for multiple cancers
through LRFN2-NMDA receptor pathway.
The locus of 7p15.3 was also annotated in Figure S4,
and SNPs in strong LD with rs2285947 are located in the
initial parts of both SP4 (Specificity Protein 4 [MIM
600540]) and DNAH11 (Dynein, axonemal, heavy chain
11 [MIM 603339]). Publicly available data of cis-expression
quantitative trait loci (eQTLs) indicate that rs7788515,
a SNP in strong LDwith rs2285947 (r2¼ 0.92), is associated
with the expression of DNAH11 (p ¼ 5.4 3 107).46
Dyneins are microtubule-associated motor protein
complexes. Functional link has been established betweenThe AmericanMAPK (mitogen-activated protein kinase) components
and dynein motors, which are indispensable for activation
of MAPK kinase3/6 and p38 in vivo.47 The p38-MAPK
pathway that is strongly activated by stress plays
important roles in the immune and inflammatory
responses48,49 as well as in the regulation of cell survival,
differentiation, and migration.50,51 However, the effects
of variants in this region could be on other genes or non-
coding regulatory elements at a distance, and further
functional studies are warranted to understand the poten-
tially functional significance of cancer risk-related locus
at 7p15.3.
In the current study, we identified two loci at 6p21.1 and
7p15.3 that may serve as susceptibility loci for multiple
cancers. Although the approach searching consistent
effects on all three cancer types used in this study may
represent a cost-efficient manner to discover loci of
pleiotropy, it may be too stringent and miss some real
loci associated with multiple cancers even though some
loci were inconsistent in one study. Therefore, further
studies by removing each study per disease may introduceJournal of Human Genetics 91, 928–934, November 2, 2012 931
more candidate loci for further replication and facilitate
to discover additional pleiotropy loci. Moreover, these
two loci were not investigated and reported in individual
cancer study previously31–33 due to relative high p values
in GWAS stage (p > 105). A genome-wide significance
was observed after combining GWAS and replication
stages for associations of rs2494938 at 6p21.1 with
NCGC (p ¼ 4.91 3 109) and rs2285947 at 7p15.3 with
lung cancer (p ¼ 1.57 3 108), suggesting that further
comprehensive replication studies for individual cancer
GWAS are required to indentify missing susceptibility loci.
In summary, our study indicates variants at 6p21.1 and
7p15.3 as candidate susceptibility loci for multiple types
of human cancer, though the biological mechanism
remains to be elucidated. Further investigations are war-
ranted to extend these findings to other types of human
cancers and to other ethnic populations.Supplemental Data
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